Abstract: The present invention relates to a pharmaceutical composition comprising topiramate, and more particularly, to a solid pharmaceutical composition comprising topiramate, a cellulose derivative, a lipid and optional pharmaceutical excipients, wherein the weight ratio of topiramate to the cellulose derivative is 100:10 to 100. The pharmaceutical compositions of the present invention have excellent formulation properties as well. The pharmaceutical compositions of the present invention can be used for monotherapy for patients who are newly diagnosed with epilepsy, or patients who have been previously treated with combination therapy and now for monotherapy. They can also be used for the add-on treatment of partial seizures in adults and children aged 2 to 16 years.

Abstract: Mixing devices and systems are disclosed for storing separate components and for mixing and dispensing those Components on demand. A mixing device includes a syringe having a generally tubular housing formed with a mixing chamber. A plunger is fitted to the tubular housing to form a first syringe. A dispensing syringe is releasably connected to the mixing chamber. At this point each syringe holds a desired amount of a mixture component. The contents of one syringe are passed through the mixing chamber to the other syringe, forming a usually incomplete mixture. The mixture is then passed through the mixing chamber to the other syringe. Multiple passes through the mixing chamber are continued until the desired mixing result is achieved, and the mixture material is contained in the second syringe that is used to thereafter dispense desired amounts of the mixture.

Abstract: Mixing devices and systems are disclosed for storing separate components and for mixing and dispensing those components on demand. A mixing device includes a syringe having a generally tubular housing formed with a mixing chamber. A plunger is fitted to the tubular housing to form a first syringe. A dispensing syringe is releasably connected to the mixing chamber. At this point each syringe holds a desired amount of a mixture component. The contents of one syringe are passed through the mixing chamber to the other syringe, forming a usually incomplete mixture. The mixture is then passed through the mixing chamber to the other syringe. Multiple passes through the mixing chamber are continued until the desired mixing result is achieved, and the mixture material is contained in the second syringe that is used to thereafter dispense desired amounts of the mixture.

Abstract: Mixing devices and systems are disclosed for storing separate components and for mixing and dispensing those components on demand. A mixing device includes a syringe having a generally tubular housing formed with a mixing chamber. A plunger is fitted to the tubular housing to form a first syringe. A dispensing syringe is releasably connected to the mixing chamber. At this point each syringe holds a desired amount of a mixture component. The contents of one syringe are passed through the mixing chamber to the other syringe, forming a usually incomplete mixture. The mixture is then passed through the mixing chamber to the other syringe. Multiple passes through the mixing chamber are continued until the desired mixing result is achieved, and the mixture material is contained in the second syringe that is used to thereafter dispense desired amounts of the mixture.

Abstract: The present invention especially relates to the use of a combination comprising (1) an ACEI selected from the group consisting of benazepril, benazeprilat, and pharmaceutically acceptable salts thereof, and (2) amlodipine or pharmaceutically acceptable salt thereof, for the manufacture a medicament for the treatment or prevention or delay of progression of a condition selected from the group consisting of hypertension, congestive heart failure, angina, myocardial infarction, artherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, blood pressure-related cerebrovasular disease, stroke, pulmonary disease or pulmonary hypertension and headache; wherein (i) the amount of amlodipine or a pharmaceutically acceptable salt thereof corresponds to 6 about mg to 40 about mg of the free base and (ii) the amount of the ACE inhibitor or a pharmaceutically thereof corresponds to 20 about mg to 160 about mg o